5-Hydroxy-l-tryptophan alters gaboxadol pharmacokinetics in rats: Involvement of PAT1 and rOat1 in gaboxadol absorption and elimination

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 1-3, 2010, Pages 68-75

  Larsen, Mie ^a   Holm, René ^b   Jensen, Klaus Gjervig ^b   Sveigaard, Christina ^b   Brodin, Birger ^a   Nielsen, Carsten Uhd ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

5 Hydroxy l tryptophan (5 HTP); Gaboxadol; hPAT1 (SLC36A1); In vivo absorption; rOat1 (Slc22a6)

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMINO ACID TRANSPORTER; COMPLEMENTARY RNA; GABOXADOL; ORGANIC ANION TRANSPORTER 1; PROTON COUPLED AMINO ACID TRANSPORTER 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; MALE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; XENOPUS;

5-HYDROXYTRYPTOPHAN; AMINO ACID TRANSPORT SYSTEMS; ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DRUG INTERACTIONS; GASTRIC EMPTYING; HUMANS; INTESTINAL ABSORPTION; ISOXAZOLES; KINETICS; MALE; OOCYTES; ORGANIC ANION TRANSPORT PROTEIN 1; RATS; RATS, SPRAGUE-DAWLEY; SYMPORTERS; XENOPUS LAEVIS;

EID: 73749084701     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.10.013     Document Type: Article

References (28)

1. Alebouyeh M., Takeda M., Onozato M.L., Tojo A., Noshiro R., Hasannejad H., Inatomi J., Narikawa S., Huang X.L., Khamdang S., Anzai N., and Endou H. Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites. J. Pharmacol. Sci. 93 (2003) 430-436
2. +/amino acid transporter 1 (PAT1) is the imino acid carrier: An intestinal nutrient/drug transporter in human and rat. Gastroenterology 127 (2004) 1410-1422
3. Angst J., Woggon B., and Schoepf J. The treatment of depression with l-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study. Arch. Psychiatr. Nervenkr. 224 (1977) 175-186
4. Apiwattanakul N., Sekine T., Chairoungdua A., Kanai Y., Nakajima N., Sophasan S., and Endou H. Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol. Pharmacol. 55 (1999) 847-854
5. Bahn A., Ljubojevic M., Lorenz H., Schultz C., Ghebremedhin E., Ugele B., Sabolic I., Burckhardt G., and Hagos Y. Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am. J. Physiol. Cell Physiol. 289 (2005) C1075-C1084
6. Chen Z., Fei Y.J., Anderson C.M.H., Wake K.A., Miyauchi S., Huang W., Thwaites D.T., and Ganapathy V. Structure, function and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2. J. Physiol. 546 (2003) 349-361
7. Chu X.Y., Liang Y., Cai X., Cuevas-Licea K., Rippley R.K., Kassahun K., Shou M., Braun M.P., Doss G.A., Anari M.R., and Evers R. Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters. Pharm. Res. 26 (2009) 459-468
8. Das Y.T., Bagchi M., Bagchi D., and Preuss H.G. Safety of 5-hydroxy-l-tryptophan. Toxicol. Lett. 150 (2004) 111-122
9. Ding X.R., Stier Jr. C.T., and Itskovitz H.D. Serotonin and 5-hydroxytryptophan on blood pressure and renal blood flow in anesthetized rats. Am. J. Med. Sci. 297 (1989) 290-293
10. Ebert B., Wafford K.A., and Deacon S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol. Ther. 112 (2006) 612-629
11. Kall M.A., Fu I., Dige T., Vallano P., Woolf E., and Jorgensen M. Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 858 (2007) 168-176
12. Khamdang S., Takeda M., Noshiro R., Narikawa S., Enomoto A., Anzai N., Piyachaturawat P., and Endou H. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 303 (2002) 534-539
13. A agonist THIP (gaboxadol) increases non-REM sleep and enhances delta activity in the rat. Neuroreport 7 (1996) 2241-2245
14. Larsen M., Holm R., Jensen K.G., Brodin B., and Nielsen C.U. Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of l-tryptophan. Br. J Pharmacol. 157 (2009) 1380-1389
15. Larsen M., Larsen B.B., Frolund B., and Nielsen C.U. Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: Characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur. J. Pharm. Sci. 35 (2008) 86-95
16. Laskin O.L., de Miranda P., King D.H., Page D.A., Longstreth J.A., Rocco L., and Lietman P.S. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob. Agents Chemother. 21 (1982) 804-807
17. Lund J., Helboe T., and Mengel H. Absorption, metabolism and excretion profile of gaboxadol in humans. Sleep 29 (2006) A41-A141
18. Metzner L., Kottra G., Neubert K., Daniel H., and Brandsch M. Serotonin, l-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J. 19 (2005) 1468-1473
19. Rizwan A.N., and Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res. 24 (2007) 450-470
20. Rowland M., and Tozer N.T. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. (1995), Lippincott Williams & Wilkins 601 p.
21. Schultz B., Aaes-Jorgensen T., Bogeso K.P., and Jorgensen A. Preliminary studies on the absorption, distribution, metabolism, and excretion of THIP in animal and man using 14C-labelled compound. Acta Pharmacol. Toxicol. (Copenh.) 49 (1981) 116-124
22. Stier Jr. C.T., and Itskovitz H.D. Formation of serotonin by rat kidneys in vivo. Proc. Soc. Exp. Biol. Med. 180 (1985) 550-557
23. Stier Jr. C.T., McKendall G., and Itskovitz H.D. Serotonin formation in nonblood-perfused rat kidneys. J. Pharmacol. Exp. Ther. 228 (1984) 53-56
24. Thwaites D.T., Basterfield L., McCleave P.M., Carter S.M., and Simmons N.L. Gamma-aminobutyric acid (GABA) transport across human intestinal epithelial (Caco-2) cell monolayers. Br. J. Pharmacol. 129 (2000) 457-464
25. +-independent) proline transport in human intestinal (Caco-2) epithelial cell monolayers. FEBS Lett. 333 (1993) 78-82
26. Turner E.H., Loftis J.M., and Blackwell A.D. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol. Ther. 109 (2006) 325-338
27. Wada S., Tsuda M., Sekine T., Cha S.H., Kimura M., Kanai Y., and Endou H. Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J. Pharmacol. Exp. Ther. 294 (2000) 844-849
28. Wang Y., Berndt T.J., Gross J.M., Peterson M.A., So M.J., and Knox F.G. Effect of inhibition of MAO and COMT on intrarenal dopamine and serotonin and on renal function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280 (2001) R248-R254